Related Experiment Video
Updated: Nov 15, 2025

Analysis of Cell Cycle Position in Mammalian Cells
Published on: January 21, 2012
The RanBP2/RanGAP1-SUMO complex gates β-arrestin2 nuclear entry to regulate the Mdm2-p53 signaling axis
Elodie Blondel-Tepaz1,2,3, Marie Leverve1,2,3, Badr Sokrat4,5
1Inserm, U1016, Institut Cochin, Paris, France.
Abstract:
Mdm2 antagonizes the tumor suppressor p53. Targeting the Mdm2-p53 interaction represents an attractive approach for the treatment of cancers with functional p53. Investigating mechanisms underlying Mdm2-p53 regulation is therefore important. The scaffold protein β-arrestin2 (β-arr2) regulates tumor suppressor p53 by counteracting Mdm2. β-arr2 nucleocytoplasmic shuttling displaces Mdm2 from the nucleus to the cytoplasm resulting in enhanced p53 signaling. β-arr2 is constitutively exported from the nucleus, via a nuclear export signal, but mechanisms regulating its nuclear entry are not completely elucidated. β-arr2 can be SUMOylated, but no information is available on how SUMO may regulate β-arr2 nucleocytoplasmic shuttling. While we found β-arr2 SUMOylation to be dispensable for nuclear import, we identified a non-covalent interaction between SUMO and β-arr2, via a SUMO interaction motif (SIM), that is required for β-arr2 cytonuclear trafficking. This SIM promotes association of β-arr2 with the multimolecular RanBP2/RanGAP1-SUMO nucleocytoplasmic transport hub that resides on the cytoplasmic filaments of the nuclear pore complex. Depletion of RanBP2/RanGAP1-SUMO levels result in defective β-arr2 nuclear entry. Mutation of the SIM inhibits β-arr2 nuclear import, its ability to delocalize Mdm2 from the nucleus to the cytoplasm and enhanced p53 signaling in lung and breast tumor cell lines. Thus, a β-arr2 SIM nuclear entry checkpoint, coupled with active β-arr2 nuclear export, regulates its cytonuclear trafficking function to control the Mdm2-p53 signaling axis.
Insights
The scaffold protein beta-arrestin2 (β-arr2) controls tumor suppressor p53 by interacting with Mdm2. A specific motif on β-arr2 is crucial for its nuclear entry, impacting cancer signaling pathways.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- Mdm2 antagonizes the tumor suppressor p53, a key target in cancer therapy.
- Beta-arrestin2 (β-arr2) counteracts Mdm2, enhancing p53 signaling through nucleocytoplasmic shuttling.
- Mechanisms regulating β-arr2 nuclear import are not fully understood.
Purpose of the Study:
- To investigate the role of SUMOylation and SUMO interaction motifs (SIMs) in regulating β-arr2 nucleocytoplasmic shuttling.
- To elucidate how β-arr2 trafficking controls the Mdm2-p53 signaling axis.
Main Methods:
- Investigated β-arr2 SUMOylation and its effect on nuclear import.
- Identified and mutated a SUMO interaction motif (SIM) in β-arr2.
- Assessed the impact of SIM mutation on β-arr2 trafficking, Mdm2 localization, and p53 signaling in lung and breast cancer cell lines.
- Examined the interaction of β-arr2 with the RanBP2/RanGAP1-SUMO complex.
Main Results:
- β-arr2 SUMOylation is dispensable for nuclear import, but a SIM is required for its cytonuclear trafficking.
- The β-arr2 SIM facilitates association with the RanBP2/RanGAP1-SUMO transport hub at the nuclear pore complex.
- Depletion of RanBP2/RanGAP1-SUMO impairs β-arr2 nuclear entry.
- SIM mutation inhibits β-arr2 nuclear import, Mdm2 delocalization, and p53 signaling in cancer cells.
Conclusions:
- A β-arr2 SIM-dependent nuclear entry mechanism, alongside constitutive nuclear export, regulates β-arr2 trafficking.
- This trafficking controls the Mdm2-p53 axis, offering potential therapeutic strategies for cancers with functional p53.
Related Concept Videos
Abnormal Proliferation
Negative Regulator Molecules
Directionality of Nuclear Transport
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
MAPK Signaling Cascades

